I’ve been keeping a close eye on the FTSE 100 in recent months. The large cap index has climbed 7% higher in 2024 but it hasn’t all been plain sailing.
In fact, there are several top stocks under pressure this year. But one pharmaceuticals giant in particular that has caught my eye and could be entering my Buy zone.
Pharma group under pressure
GSK (LSE: GSK) is one of the FTSE 100 stocks that’s on my radar. It’s a famous industry name and one of the largest pharmaceuticals and biotechnology companies in the world.
Despite its status, the GSK share price has been under pressure, falling 26.2% since May 15 to sit at 1,335p per share.
One of the biggest factors weighing on the group’s valuation has been ongoing lawsuits surrounding its heartburn drug Zantac in the US.
However, GSK has agreed a $2.2bn settlement to end most of these lawsuits with a related £1.8bn charge booked in Q3 this year.
CEO Emma Walmsley said: “[We] resolved the vast majority of Zantac litigation in the quarter, to remove uncertainty and so we can focus forward. All this means we are on track to deliver our 2024 guidance.”
Despite seeing its share price slide in 2024, GSK is still one of the biggest companies in the FTSE 100 with a market cap of £56bn.
Recent performance
GSK reported £8.01bn in Q3 sales back in October which marginally missed analyst estimates of £8.05bn. However, there were some bright spots with core earnings per share (EPS) beating estimates and climbing 5% to 47.9p.
That was driven by 19% growth in Speciality Medicines sales thanks to strong oncology and HIV sales. Another aspect I really like is GSK’s growing pipeline with 11 positive phase-3 trials so far.
However, increasing competition in the respiratory syncytial virus (RSV) market, driven by a US advisory committee’s regulatory guideline revisions, has put a bit of a dampener on the growth outlook.
Valuation
GSK has a price-to-earnings (P/E) ratio of 22 right now. For some context, the Footsie is valued at around 14.5 times earnings.
That premium in itself doesn’t necessarily turn me off. P/E ratios vary by industry, and pharma companies can command a higher premium given the industry’s non-cyclical nature.
I’m more interested in how GSK stacks up against peers. AstraZeneca is a natural comparison as another major global player in the Footsie.
The company is trading at 32.5 times earnings with a £164bn market cap. AstraZeneca has been growing revenue and earnings, driven by organic growth and a number of key acquisitions in recent years.
In fact, management wants to grow total revenue from £45.8bn in 2023 to £80bn by 2030. That’s an ambitious plan, but one that could pay off handsomely for investors.
The verdict
I don’t think GSK is out of the woods yet. Confirmed full-year guidance including sales growth of 7% to 9% and core EPS growth of 10% to 12% certainly helps.
My target multiple for the FTSE 100 stock is 20 times earnings. I think that would compensate me for the risks while being a significant discount to AstraZeneca.
For the moment, I’ll be saving my money so I can buy if GSK falls into my Buy zone.
The post Why this falling FTSE 100 stock could be entering my Buy zone appeared first on The Motley Fool UK.
5 Shares for the Future of Energy
Investors who don’t own energy shares need to see this now.
Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.
While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.
Open this new report — 5 Shares for the Future of Energy — and discover:
Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
How to potentially get paid by the weather
Electric Vehicles’ secret backdoor opportunity
One dead simple stock for the new nuclear boom
Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!
Grab your FREE Energy recommendation now
More reading
Down 25% with a 4.32% yield and P/E of 8.6! Is this my best second income stock or worst?
After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?
Is GSK a bargain now the share price is near 1,333p?
Down 28%! What’s going on with GSK’s share price?
This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks
Ken Hall has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
